Methods of manufacture of therapeutic products comprising vitalized placental dispersions

Patent metadata

Field	Value
Publication number	US-12318408-B2
Application number	US-202318101727-A
Country	US
Kind code	B2
Filing date	Jan 26, 2023
Priority date	Feb 18, 2010
Publication date	Jun 3, 2025
Grant date	Jun 3, 2025

Abstract

This invention provides a fluid therapeutic placental product comprising placental cells and a placental dispersion comprising placental factors. The placental cells and the placental dispersion are derived from placental tissue. A placental tissue can optionally be an amnion, chorion, or a trophoblast-depleted chorion. The placental product of the present invention is useful in treating a patient with a tissue injury (e.g. wound or burn) by applying the placental product to the injury. Similar application is useful with ligament and tendon repair and for engraftment procedures such as bone engraftment.

First claim

The invention claimed is:

1. A method of treating a tissue injury in a patient, the method comprising:
a) obtaining a placental dispersion comprising:
(i) disrupted chorionic tissue; and
(ii) placental cells from chorionic tissue, wherein the placental cells are not cultured or expanded ex vivo, and
wherein the chorionic tissue is substantially free of trophoblasts; and

b) applying the placental dispersion to the tissue injury.

2. The method of claim 1 , wherein the disrupted chorionic tissue is derived from the same chorionic tissue as the placental cells.

3. The method of claim 2 , further comprising enzymatically digesting the chorionic tissue before disrupting the chorionic tissue to provide the disrupted chorionic tissue.

4. The method of claim 1 , wherein the disrupted chorionic tissue is derived from a chorionic tissue that is different from the chorionic tissue from which the placental cells are derived.

5. The method of claim 1 , wherein the placental cells comprise one or more of mesenchymal stem cells, embryonic stem cells, placenta-derived mesenchymal progenitor cells, placental mesenchymal stem cells, fibroblasts, epithelial cells, placental mesenchymal cells, stromal cells, macrophages, or combinations thereof.

6. The method of claim 1 , wherein the placental cells are present at a concentration of at least about 20,000 per ml of the placental dispersion.

7. The method of claim 1 , wherein the placental dispersion further comprises one or more placental-derived factors.

8. The method of claim 7 , wherein the one or more placental-derived factors comprises one or more of extracellular matrix proteins, angiogenic factors, chemokines, cytokines, growth factors, matrix metalloproteinases, or combinations thereof.

9. The method of claim 7 , wherein the one or more placental-derived factors are produced by the placental dispersion up to 14 days after application to the tissue injury.

10. The method of claim 1 , wherein the placental dispersion is thawed after cryopreservation of the placental dispersion.

11. The method of claim 1 , wherein the placental dispersion is rehydrated after lyophilization of the placental dispersion.

12. The method of claim 1 , wherein the placental dispersion is applied to about 1 cm 2 to about 100 cm 2 of the tissue injury.

13. The method of claim 1 , wherein the placental dispersion has a viscosity of 1,000 cps to 15,000 cps or 20,000 cps to 200,000 cps.

14. The method of claim 1 , wherein the placental dispersion does not comprise ex vivo expanded or cultured cells.

15. The method of claim 1 , wherein the placental dispersion is formulated with one or more thickening agents, antibiotics, emollients, keratolytic agents, humectants, anti-oxidants, preservatives, electrolyte solutions, albumin, or combinations thereof.

16. The method of claim 1 , wherein the placental dispersion is comprised in a bandage or wound dressing.

17. The method of claim 1 , wherein the placental dispersion is comprised in an implant.

18. The method of claim 1 , wherein the tissue injury is a burn, wound, ulceration, laceration, ablations, or surgical incision.

Assignees

• Osiris Therapeutics Inc

Inventors

• Tom Samson
• Danilkovitch Alla
• Yoo Dana
• Jansen Timothy
• Kuang Jin-Qiang
• Marconi Jennifer Michelle

Classifications

• C12N2501/115

  Basic fibroblast growth factor (bFGF, FGF-2) · CPC title

• C12N5/0605

  Cells from extra-embryonic tissues, e.g. placenta, amnion, yolk sac, Wharton's jelly · CPC title

• A61K38/57

  from animals; from humans {(A61K38/553, A61K38/556 take precedence)} · CPC title

• A61K38/39

  Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG] · CPC title

• A61K38/1841

  Transforming growth factor [TGF] · CPC title